Biologics, early treatment, and lifestyle choices take the spotlight in rheumatoid arthritis advances.
A lack of national standards and less than optimal oversight of many inpatient, opioid addiction rehabilitation programs is raising questions about the level of services, personnel, and quality of care many patients are receiving.
Switzerland-based pharma company Roche’s $1.9 billion purchase of tech company Flatiron Health signifies Big Pharma’s need for data.
Successful CAR T-cell therapy reimbursement begins with careful payer-provider collaboration and taking these two approaches.
A study from Human Rights Watch has eye-opening findings about antipsychotic drug prescribing in U.S. nursing homes.
We asked the Managed Healthcare Executive board to share their favorite app—for work or for play. Here’s what they said.
Retail drug chain giant Walgreens made a takeover approach to drug distributor AmerisourceBergen. Here’s what industry watchers want you to know about it.
The healthcare landscape is transforming. Here are six considerations to help your talent during restructuring, downsizing, and other transitions.
Here are three strategies to navigate toward next-generation care management and increase member engagement in the process
Understanding the key barriers to biosimilar adoption in the U.S. is the first step managed care executives can take to overcome these obstacles, according to a Trinity Parners report.